Abnormal bleeding can feel alarming, especially after menopause. If you are worried about abnormal bleeding, remember that a scan alone cannot confirm the diagnosis. Doctors need a tissue sample from the uterine lining.
Most abnormal bleeding is caused by conditions other than cancer. Still, prompt medical review provides clear answers and helps your doctor decide which tests are appropriate.
Quick Answer
In Malaysia, suspected cancer of the uterine lining is usually assessed after postmenopausal bleeding, bleeding between periods, or unusually heavy or prolonged periods. Your doctor may start with a pelvic examination and transvaginal ultrasound, then arrange tissue sampling from the uterine lining if needed.
A pathology report from the tissue sample confirms whether cancer cells are present. If the condition is confirmed, MRI, CT, or PET scans may assess its extent. These scans help with staging, rather than confirming the diagnosis itself.
A Pap smear is useful for cervical screening, but it does not reliably assess the uterine lining.
Key Takeaways
- Any bleeding after menopause needs prompt review by a doctor or gynaecologist.
- A transvaginal ultrasound can assess the uterus, but it cannot confirm cancer.
- A biopsy and pathology review are usually needed to confirm the diagnosis.
- Final staging may depend on scans, surgery, and the pathology report.
- Molecular or biomarker testing may help your cancer specialist guide treatment.
- A second opinion can be useful when results are unclear or several treatment options are being discussed.
When Abnormal Bleeding Needs a Gynaecology Review
Endometrial carcinoma begins in the lining inside the uterus and is the most common form of uterine cancer.
The most recognised symptom is postmenopausal bleeding, even if it happens once or seems light. You should also arrange a review if you have bleeding between periods, periods that become much heavier or longer than usual, watery or blood-stained discharge, or new pelvic pressure.
Some factors can raise your likelihood of developing this disease. These include older age, obesity, diabetes, polycystic ovary syndrome, long-term irregular ovulation, and taking oestrogen without progesterone when you still have a uterus. Tamoxifen use and Lynch syndrome can also matter.
These risk factors do not mean you have the condition. On the other hand, you can develop this disease without any known risk factor. Your symptom pattern, menstrual history, medicines, family history, and examination findings all shape the next step.
There is no routine population cancer screening programme for average-risk women. The National Cancer Institute also states that there is no proven reliable screening test for this condition. Therefore, symptom-triggered assessment remains important for early detection, because no reliable routine screening test is established for average-risk women.
Endometrial Cancer Diagnosis Malaysia: The Usual Pathway
The usual diagnostic pathway in Malaysia starts with a gynaecologist. If results raise concern, you may be referred to a gynaecologic oncologist, a specialist in cancers of the female reproductive system.
The sequence can vary, and the table outlines the main diagnostic tools used during assessment. An ultrasound may come first; a biopsy may be needed sooner based on age, bleeding pattern, or examination findings.
| Test or assessment | What it helps your doctor assess |
|---|---|
| Medical history and pelvic examination | Bleeding pattern, possible causes, risk factors, and visible abnormalities |
| Transvaginal ultrasound | Endometrial thickness, fibroids, polyps, ovarian findings, and uterine changes |
| Endometrial biopsy | Whether cancer or pre-cancerous cells are present |
| Hysteroscopy or D&C | Direct inspection and additional tissue sampling when needed |
| MRI, CT, or PET scan | Possible local spread, lymph nodes, or disease outside the uterus |
The approach reflects current clinical practice, as outlined in current ESMO guidance. It includes clinical assessment, imaging where needed, and histological confirmation before treatment planning.
Transvaginal ultrasound is a first look, not a final answer
A transvaginal ultrasound uses a slim probe placed in the vagina to create images of the uterus and ovaries. It can show whether the uterine lining appears thickened, uneven, or affected by a polyp or fibroid.
For postmenopausal bleeding, a thin uterine lining may lower concern. However, the result does not replace a biopsy when symptoms persist, risk factors are present, or the scan is unclear. Your doctor will interpret the measurement alongside your history.
If you are not comfortable with a transvaginal scan, tell the clinic. You can ask why it is recommended, how it will be performed, and whether another approach is suitable.
Endometrial biopsy confirms the cancer diagnosis
An endometrial biopsy is often the key test. A doctor passes a thin tube, sometimes called a Pipelle, through the cervix to collect cells from the uterine lining. It is often done in a clinic and can cause period-like cramping.
The laboratory examines the tissue under a microscope. A pathology report may identify cancer type, grade, and other features that affect treatment discussions.
Sometimes the sample is too small or does not explain ongoing bleeding. Depending on the first sample’s quality, your doctor may recommend diagnostic procedures such as hysteroscopy, where a small camera views the uterine cavity, or dilatation and curettage (D&C), which collects more tissue under anaesthesia.
Imaging and blood tests help plan the next stage
After confirmation, advanced imaging helps doctors assess whether the disease is limited to the uterus or has spread. An MRI scan for cancer can give detailed information about the uterus and nearby tissues. A CT scan for cancer may assess the chest, abdomen, and pelvis.
A PET scan for cancer may be considered when doctors need more information about lymph nodes or possible spread. These scans support staging and treatment planning, but they do not replace tissue confirmation.
Your doctor may request blood tests, including CA-125 in selected cases. This tumour marker test is not reliable enough to confirm the diagnosis by itself. It forms only one part of the wider assessment.
Keep copies of your ultrasound report, biopsy result, scan discs, and referral letters. A clear medical report review is easier when all records are available.
Cancer Stages, Pathology, and Molecular Profiling
Cancer stages describe how far a cancer has grown or spread. Broadly, stage I is confined to the uterus, while later stages involve nearby structures, lymph nodes, or distant sites. Scans may suggest a preliminary stage, but surgery and pathology can change it.
Pathology now looks beyond whether cancer is present. Depending on the case and hospital availability, tumor profiling may include mismatch repair protein testing, p53 assessment, and POLE genetic testing. These findings may prompt cancer genetics counselling or Lynch syndrome assessment, especially alongside age and family history.
Molecular profiling can characterize tumor biology and support precision medicine. It helps your oncologist estimate risk and discuss radiation therapy, chemotherapy, immunotherapy, targeted therapy, or closer follow-up. Genomic sequencing may be considered in selected cases, based on pathology, specialist advice, and local availability. Results inform these discussions, but don’t guarantee a particular treatment.
The Pan-Asian adapted ESMO guidance on diagnosis and follow-up reflects how pathology, imaging, genetic assessment, and patient factors guide clinical decisions. Biomarker testing is useful, but it does not replace an individual medical assessment.
Artificial intelligence may assist radiologists and pathologists with image analysis in some settings. It cannot diagnose cancer independently, and molecular profiling does not select treatment on its own. A qualified clinician must interpret the findings, confirm the tissue result, and review the pathology report with you.
Cancer Treatment Options After Diagnosis
Uterine cancer treatment depends on stage, histology, scan findings, biomarkers, medical history, treatment goals, and specialist assessment. A specialist team may include a surgeon, radiation oncologist, pathologist, and medical oncologist when systemic treatment is being considered.
For many people with cancer confined to the uterus, surgery is the main treatment. This commonly involves removing the uterus, fallopian tubes, and ovaries. The surgeon may also assess lymph nodes, sometimes using sentinel lymph-node mapping.
After surgery, the pathology report helps your team decide whether further treatment is needed. Radiotherapy may involve external-beam radiation therapy, brachytherapy near the treatment area, or both. These approaches can reduce the chance of recurrence in selected cases.
Chemotherapy may be discussed for higher-risk, advanced, or recurrent disease. Hormone therapy may suit some hormone-sensitive cancers. Immunotherapy or targeted therapy may be options for selected tumour profiles, particularly when mismatch repair testing shows relevant changes.
Advanced cancer treatment is never one-size-fits-all. A personalized treatment plan may differ according to disease features, other health conditions, and treatment goals. Risk, stage, and treatment evidence may inform discussions about prognosis and survival outcomes, without predicting an individual result. The Pan-Asian endometrial cancer practice guideline describes this risk-based approach to surgery, systemic treatment, and follow-up.
Choosing a Cancer Specialist, Hospital, and Second Opinion
When arranging cancer treatment in Malaysia, you can begin with a gynaecologist and see a gynaecologic oncologist if cancer is suspected or confirmed. A medical oncologist may focus on medicines and other non-surgical treatments.
A hospital with coordinated oncology care can bring together surgery, pathology, radiology, radiation oncology, medical oncology, and supportive services. Multidisciplinary discussions can help specialists review complex cases across these specialties. Ask whether supportive care includes symptom management, rehabilitation, and emotional or psychosocial support, including psycho-oncology services.
Hospitals and centres listing gynaecology or gynae-oncology services include Avisena Women’s & Children’s Specialist Hospital in Shah Alam, Beacon Hospital, Columbia Asia Hospital Malaysia, Pantai Hospitals, Gleneagles Hospital Penang, and Hospital Universiti Sains Malaysia. Verify current gynae-oncology services, test availability, and referral requirements before relying on any listing.
A cancer second opinion can help if you have a rare pathology type, unclear scan findings, recurrent cancer, or different treatment options to consider. Bring your pathology slides if requested, full scan images and reports, and a current list of medicines. A cancer treatment plan review should focus on the diagnosis, proposed treatment, expected purpose, and reasonable alternatives.
A useful second opinion reviews the original biopsy and scans, rather than only repeating a brief summary of the diagnosis.
Cancer treatment costs can vary widely because surgery, hospital stays, specialist fees, imaging, laboratory testing, radiotherapy, and medicines are billed differently. When comparing healthcare in Malaysia, ask for an itemised quotation and clarify what it includes. You can also ask about waiting times, insurance pre-authorisation, public or private referral pathways, and likely follow-up expenses.
If you are considering overseas cancer treatment, treat hospital matching or coordination services as information support only. Your own oncologist should review whether travel, timing, and treatment access are medically appropriate.
Questions to Ask During Your Oncology Consultation
Write your questions down before the appointment. You may want to ask:
- What does my biopsy and pathology report show, including the cancer grade and molecular test results?
- Which findings are confirmed, and which are still provisional?
- What records, scans, and reports should I bring to future appointments?
- Do I need an MRI, CT, or PET scan before treatment?
- What is my likely stage now, and could surgery change the final stage?
- Which treatment do you recommend, and why does it fit my case? What is the main goal of treatment?
- What side effects should I expect from surgery, radiotherapy, chemotherapy, hormone therapy, or immunotherapy?
- Should I seek a cancer second opinion or request a pathology report review?
- When will I receive the next results, and when should I schedule follow-up?
- What costs should I expect before, during, and after treatment?
Final Thoughts
Abnormal bleeding deserves attention, but it does not automatically mean cancer. A prompt examination, appropriate imaging, and an endometrial biopsy can turn uncertainty into a clear diagnosis.
After a confirmed result, your care team can use pathology, scans, staging, and biomarker findings to discuss a treatment plan suited to your individual situation.
Frequently Asked Questions
Can an ultrasound diagnose endometrial cancer?
No. A transvaginal ultrasound can show changes in the uterine lining and indicate whether further tests are needed. A biopsy or another tissue-sampling procedure is needed to confirm cancer.
Is bleeding after menopause always caused by cancer?
No. Polyps, thinning of the vaginal or uterine lining, hormone medicines, fibroids, and other conditions can cause bleeding. However, don’t ignore postmenopausal bleeding because it still needs medical assessment.
Does every patient need genetic testing for cancer?
Not every patient needs the same tests. Your specialist may recommend tumour testing or genetic counselling based on pathology findings, your age at diagnosis, family history, and signs of inherited cancer risk.
When should you seek urgent medical care?
Seek urgent help if bleeding soaks pads quickly, you feel faint, or you have severe pelvic pain, chest pain, shortness of breath, or a high fever. For less severe but unexplained bleeding, arrange a clinic appointment as soon as possible.
Medical Disclaimer
This content is for general information only and may not be fully verified or applicable to every patient. It is not medical advice, a diagnosis, or a treatment recommendation. You should consult your own doctor, oncologist, or another qualified healthcare professional before making any medical decision. SureLah does not accept responsibility for medical decisions, treatment outcomes, doctor recommendations, hospital choices, or patient actions based on this article.
